SE9501671D0 - Method and composition for prevention of posterior capsule opacification - Google Patents

Method and composition for prevention of posterior capsule opacification

Info

Publication number
SE9501671D0
SE9501671D0 SE9501671A SE9501671A SE9501671D0 SE 9501671 D0 SE9501671 D0 SE 9501671D0 SE 9501671 A SE9501671 A SE 9501671A SE 9501671 A SE9501671 A SE 9501671A SE 9501671 D0 SE9501671 D0 SE 9501671D0
Authority
SE
Sweden
Prior art keywords
posterior capsule
composition
prevention
capsule opacification
surgery
Prior art date
Application number
SE9501671A
Other languages
English (en)
Swedish (sv)
Inventor
Katarina Edsman
Carl-Gustaf Goelander
Kerstin Wickstroem
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9501671A priority Critical patent/SE9501671D0/xx
Publication of SE9501671D0 publication Critical patent/SE9501671D0/xx
Priority to PCT/SE1996/000588 priority patent/WO1996034629A1/en
Priority to DE69634080T priority patent/DE69634080T2/de
Priority to AT96914498T priority patent/ATE285252T1/de
Priority to JP8533247A priority patent/JPH11504342A/ja
Priority to AU57840/96A priority patent/AU5784096A/en
Priority to EP96914498A priority patent/EP0825877B1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
SE9501671A 1995-05-05 1995-05-05 Method and composition for prevention of posterior capsule opacification SE9501671D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE9501671A SE9501671D0 (sv) 1995-05-05 1995-05-05 Method and composition for prevention of posterior capsule opacification
PCT/SE1996/000588 WO1996034629A1 (en) 1995-05-05 1996-05-03 Method and composition for prevention of posterior capsule opacification
DE69634080T DE69634080T2 (de) 1995-05-05 1996-05-03 Mittel zur verhinderung der truebung der vorderen linsenkapsel
AT96914498T ATE285252T1 (de) 1995-05-05 1996-05-03 Mittel zur verhinderung der truebung der vorderen linsenkapsel
JP8533247A JPH11504342A (ja) 1995-05-05 1996-05-03 水晶体後嚢の不透明化を予防するための方法および組成物
AU57840/96A AU5784096A (en) 1995-05-05 1996-05-03 Method and composition for prevention of posterior capsule opacification
EP96914498A EP0825877B1 (de) 1995-05-05 1996-05-03 Mittel zur verhinderung der truebung der vorderen linsenkapsel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501671A SE9501671D0 (sv) 1995-05-05 1995-05-05 Method and composition for prevention of posterior capsule opacification

Publications (1)

Publication Number Publication Date
SE9501671D0 true SE9501671D0 (sv) 1995-05-05

Family

ID=20398207

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9501671A SE9501671D0 (sv) 1995-05-05 1995-05-05 Method and composition for prevention of posterior capsule opacification

Country Status (7)

Country Link
EP (1) EP0825877B1 (de)
JP (1) JPH11504342A (de)
AT (1) ATE285252T1 (de)
AU (1) AU5784096A (de)
DE (1) DE69634080T2 (de)
SE (1) SE9501671D0 (de)
WO (1) WO1996034629A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491721B2 (en) 1998-04-15 2002-12-10 Alcon Manufacturing, Ltd. Toric intraocular lens material
ATE206314T1 (de) 1998-04-15 2001-10-15 Alcon Lab Inc Beschichtungszusammensetzung für intraocularen linsen
US6455318B1 (en) 1998-04-15 2002-09-24 Alcon Manufacturing, Ltd. Collagen IV adhesion assay for intraocular lens materials
US6482230B1 (en) 1998-04-15 2002-11-19 Alcon Manufacturing, Ltd. Lens epithelial cell growth assay for intraocular lens materials
CA2317757C (en) * 1998-04-15 2008-03-25 Alcon Laboratories, Inc. Bicomposite intraocular lens and method for its preparation
SE0402272D0 (sv) 2004-09-21 2004-09-21 Amo Groningen Bv Methods of treating a body site with a viscoelastic preparation
EP1791523B1 (de) * 2004-09-21 2013-10-23 AMO Groningen B.V. Methode zur herstellung einer viskoelastischen lösung
WO2014153394A1 (en) * 2013-03-21 2014-09-25 Genisphere, Llc Cellular delivery of dna intercalating agents
EP3416671A4 (de) 2016-02-19 2019-10-30 Genisphere, LLC Nukleinsäureträger und therapeutische verfahren zur verwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2014244A1 (en) * 1989-04-13 1990-10-13 Takeda Chemical Industries, Ltd. Stabilized composition of anthracyclines

Also Published As

Publication number Publication date
JPH11504342A (ja) 1999-04-20
ATE285252T1 (de) 2005-01-15
EP0825877A1 (de) 1998-03-04
EP0825877B1 (de) 2004-12-22
DE69634080D1 (de) 2005-01-27
WO1996034629A1 (en) 1996-11-07
AU5784096A (en) 1996-11-21
DE69634080T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
NZ314442A (en) Extended release formulation comprising venlafaxine hydrochloride, film coating composition
ATE216241T1 (de) Sehr niedrigdosiertes orales kontrazeptiv mit weniger menstruationsblutungen und verzögerter wirkung
IL109800A (en) Sustained release drug formulation containing a tramadol salt comprising cellulose ether and/or cellulose ester having a viscosity between 3,000 and 150,000 mPas
BG104476A (en) Therapeutical form for tolterodin with controlled release
MX9700850A (es) Formulaciones y metodos para proporcionar anestesia local prolongada.
GEP20012549B (en) Pharmaceutical Composition Containing Sumatriptan
IL96900A0 (en) Pharmaceutical composition containing naproxen
AU4121297A (en) Galenic form with extended release of milnacipran
AU6136199A (en) Dosage form comprising therapeutic formulation
GR3036798T3 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
MEP36008A (hr) Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
MY130098A (en) Local drug delivery film for periodontal treatment
EP0866656A4 (de) Inhibierung des alpha tumornekrose-faktors
SE9501671D0 (sv) Method and composition for prevention of posterior capsule opacification
MY124465A (en) Reduction of infarct volume using citicoline
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
PL317996A1 (en) Carbamazepinic form of a drug with retarded release of biologically active substance
KR960703593A (ko) (R)-암로디핀에 의한 평활근 세포 이동의 억제 (Inhibition of Smooth Muscle Cell Migration by (R)-Amlodipine)
GEP20043377B (en) Pharmaceutical Complex
EP0743068A3 (de) Zusammensetzung zur Hemmung von Knochenverlust welche Vanadylsulfat enthält
GB9420748D0 (en) 1,5 benzodiazepine derivatives
MY114610A (en) Controlled drug delivery system for diltiazem.